Akeso vs Merck: China’s Lung Cancer Showdown Nobody Asked For
Akeso, the Chinese biotech underdog, decided to keyboard-warrior challenge Merck’s cancer titan Keytruda with its own lung cancer drug—because what the world needed was another medical cage match. They boldly claimed increased patient survival, which is nice, but how much longer can we use ‘survival’ as a marketing pitch without sounding like a reality TV show eviction notice? Details like trial timelines, money spent, and precise survival rates were mercifully absent—maybe next press release. Meanwhile, in some lab somewhere, a scientist is probably wondering why their name isn’t in this brief yet operatic drama.
Share the Story
(1 of 3)Nothing says biotech bragging rights like promising to out-survive Merck's star drug while leaving everyone guessing the fine print. The lung cancer weapon race now has a new player, and surprisingly, no one flinched. Medical turf wars: battle royale edition.
China’s Akeso crashing Merck’s cancer party with some vague survival talk. Watch as pharmaceutical diplomacy turns into a gladiator match, minus the lions but double the patent battles.
Akeso just whispered ’survival’ louder than Merck’s Keytruda, proving in biotech PR that shouting hopeful words sometimes counts more than numbers. Meanwhile, patients wait for footnotes.
Source: Statnews | Published: 8/26/2025 | Author: Jonathan Wosen
More Articles in Health
Motorola Razr Flip Phones Finally Told They’re Secure Enough for 2027
KPMG’s Consulting Business Dies Dramatically While Staff Take a Hike
America Tries Staying Cool While Secretly Preparing For Wattocalypse
90-Year-Old Dad Outsources Bathing to Jovial Nigerian and Ghanaian Carers
Woman Ages Backwards in Online Writing Class, Still Loses to 21-Year-Old
Billionaire’s Daughter’s Brain Hemorrhage Detected Belatedly By $299 Ring
Dietitians Unite to Demand We Eat More Beans, Save Humanity from Boredom
Mark Cuban Declares AI Too Empathetic to Replace Doctors, Only Bullshit Jobs Fear
